Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 12/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.46 |
| ▸ | PDE4A | P27815 | 10/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12923593 | 0.82 | PDE4B (0.58) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6876003 | 0.80 | PDE4D (0.48) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL17207624 | 0.77 | PDE4D (0.45) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL1027909 | 0.74 | PDE4D (0.74) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL8007015 | 0.74 | PDE4D (0.47) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL7359780 | 0.74 | PDE4B (0.76) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL17207626 | 0.73 | PDE4D (0.46) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL8006958 | 0.70 | PDE4D (0.50) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL15763184 | 0.70 | PDE4B (0.60) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL14458154 | 0.70 | PDE4B (0.60) | PDE4DPDE4BPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | PDE4D 2679/4885PDE4B 2412/4885PDE4A 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.